Surgery Partners, a leading short-stay surgical facility operator, announced a 4.5% revenue increase to $810.9 million in Q1 2026, driven by a 4.4% rise in same-facility revenues and a slight 0.6% increase in cases. Despite a net loss of $35.9 million, the company posted an Adjusted EBITDA of $102.3 million, close to last year's level. It reaffirmed its 2026 revenue guidance of $3.35 to $3.45 billion and Adjusted EBITDA of at least $530 million, citing strong fundamentals and ongoing cost management. The company remains focused on physician recruitment and portfolio optimization to drive long-term growth and operational excellence.
Dycom Industries reported a record first quarter with contract revenues up 56.1% to $1.965 billion and adjusted net income nearly doubling to $134.3 million. The company raised its full-year fiscal 2027 revenue outlook to $7.38-$7.65 billion, driven ...
BrewDog, part of Tilray Brands, is rolling out a major summer campaign across the UK tied to the global football tournament. The campaign features a "Win a Year of Beer" contest with special cans hidden in over 2.8 million packs at major retailers, p...
Autolus Therapeutics, a biopharmaceutical company specializing in next-generation T cell therapies, announced it will present at two upcoming investor conferences: William Blair’s Growth Stock Conference on June 2 and Jefferies Global Healthcare Conf...
G-III Apparel Group announced a quarterly cash dividend of $0.10 per share, payable on July 8, 2026, to shareholders of record as of June 22, 2026. This dividend reflects the company's ongoing commitment to returning value to its investors. G-III is ...
Atea Pharmaceuticals announced Phase 1 results indicating their Hepatitis C treatment regimen, combining bemnifosbuvir and ruzasvir, has a low risk of drug-drug interactions with common medications like omeprazole and rosuvastatin. This supports easi...
